Arcturus Therapeutics Holdings Net Debt 2011-2026 | ARCT

Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities^[1]

Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.

Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.

Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.

Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.

Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.

Annual Net Debt Arcturus Therapeutics Holdings

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-208 M	-262 M	-358 M	-328 M	-448 M	-50.7 M	-26.8 M	-25 M	-2.17 M	-16.7 M	-2.18 M	-22.1 M	565 K	-55 K

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
565 K	-448 M	-125 M

References

Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.

Net Debt of other stocks in the Biotechnology industry

Issuer	Net Debt	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	163 M	-	2.43 %	$ 254 M	Germany
AgeX Therapeutics AGE	12.6 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	-30.2 M	-	-	$ 1.01 B	USA
Autolus Therapeutics plc AUTL	-187 M	$ 1.37	-8.67 %	$ 350 M	Britain
Adagene ADAG	-71 M	$ 1.65	3.77 %	$ 92.9 M	China
Alterity Therapeutics Limited ATHE	-34.7 M	$ 3.4	-3.41 %	$ 8.18 B	Australia
Arrowhead Pharmaceuticals ARWR	-115 M	$ 66.18	0.38 %	$ 8.85 B	USA
Biogen BIIB	4.01 B	$ 179.22	-3.45 %	$ 26.1 B	USA
Alexion Pharmaceuticals, Inc. ALXN	-402 M	-	-	$ 40.3 B	USA
Biophytis SA BPTS	-4.01 M	-	-13.47 %	$ 169 M	France
Akero Therapeutics AKRO	-340 M	-	-	$ 3.67 B	USA
AVROBIO AVRO	-76.6 M	-	1083.1 %	$ 745 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	-824 K	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	-6.17 M	-	-18.52 %	$ 27.3 M	Britain
AstraZeneca PLC AZN	9.86 B	$ 94.23	0.64 %	$ 96.9 B	Britain
BeiGene, Ltd. BGNE	-2.44 B	-	0.49 %	$ 251 B	Cayman-islands
Bellicum Pharmaceuticals BLCM	-34.7 M	-	-9.72 %	$ 5.89 M	USA
Berkeley Lights BLI	-60.5 M	-	-7.31 %	$ 87 M	USA
Институт стволовых клеток человека ISKJ	246 M	-	-	-	Russia
Ascendis Pharma A/S ASND	-195 M	$ 214.43	2.72 %	$ 5 B	Danmark
Codiak BioSciences CDAK	-39.4 M	-	-55.98 %	$ 2.15 M	USA
ARCA biopharma ABIO	-60.6 M	-	1052.0 %	$ 415 M	USA
Bristol-Myers Squibb Company BMY	37.4 B	$ 56.12	0.63 %	$ 114 B	USA
Cerevel Therapeutics Holdings CERE	-33.6 M	-	-	$ 7.29 B	USA
Acasti Pharma ACST	-27.4 M	-	4.01 %	$ 150 M	Canada
Caladrius Biosciences CLBS	-22.3 M	-	-16.75 %	$ 25.8 M	USA
BioLineRx Ltd. BLRX	-13.9 M	$ 2.88	0.52 %	$ 908 M	Israel
Clearside Biomedical CLSD	-27.9 M	-	-	$ 25.3 M	USA
Chimerix CMRX	-25.8 M	-	-	$ 756 M	USA
Adaptimmune Therapeutics plc ADAP	-119 M	-	-15.15 %	$ 60.3 M	Britain
BioNTech SE BNTX	-973 M	$ 106.68	4.4 %	$ 27.2 B	Germany
Can-Fite BioPharma Ltd. CANF	-3.5 M	$ 4.11	-2.61 %	$ 8.94 B	Israel
AIkido Pharma AIKI	-1.04 M	-	1.93 %	$ 17.4 M	USA
Catalyst Biosciences CBIO	-33.1 M	$ 11.04	0.55 %	$ 727 M	USA
Albireo Pharma ALBO	-239 M	-	-0.23 %	$ 916 M	USA
CureVac N.V. CVAC	-783 M	-	-	$ 867 M	Germany
Acer Therapeutics ACER	-2.08 M	-	2.71 %	$ 14 M	USA
Alpine Immune Sciences ALPN	-63.9 M	-	-	$ 2.17 B	USA
AlloVir ALVR	-62.7 M	-	4.14 %	$ 49.1 M	USA
Ayala Pharmaceuticals AYLA	-657 K	-	-	$ 7.46 M	Israel
Coherus BioSciences CHRS	-101 M	$ 1.7	3.03 %	$ 160 M	USA
Ampio Pharmaceuticals AMPE	-12 M	-	-11.43 %	$ 502 K	USA
Amphastar Pharmaceuticals AMPH	469 M	$ 29.26	-0.48 %	$ 1.42 B	USA
Celldex Therapeutics CLDX	-24.5 M	$ 26.03	1.4 %	$ 1.68 M	USA
CTI BioPharma Corp. CTIC	18.3 M	-	-	$ 1.2 B	USA
Cellectis S.A. CLLS	-206 M	$ 4.26	-0.12 %	$ 116 M	France
Acorda Therapeutics ACOR	114 M	-	-24.86 %	$ 820 K	USA
Applied Molecular Transport AMTI	-56.5 M	-	-	$ 10.1 M	USA
Brickell Biotech BBI	-29.7 M	-	-5.38 %	$ 6.06 M	USA
Burford Capital Limited BUR	-135 M	$ 9.61	-0.36 %	$ 1.55 B	Britain